CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute ...

CalciMedica has secured FDA alignment on the design of its Phase 2b trial for Auxora, a treatment for acute pancreatitis. The agreement covers key trial endpoints and a biomarker-based patient selection strategy, establishing a potential regulatory pathway in a disease area with no currently approved therapies.

This Wire brief sits within Fusion42's coverage of Biotech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.